Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Transcatheter Technologies GMBH

Truly repositionable transcatheter aortic valve implant

This article was originally published in Start Up

Executive Summary

A major limitation of existing transcatheter aortic heart valves is that they are unable to be repositioned once implanted. For these devices, the valve is mounted in a metal stent that contains a balloon, which is inflated once the valve is placed. The valve is then anchored to the heart wall. Transcatheter Technologies GMBH believes its fully repositionable Trinity valve will solve this shortcoming. Once Trinity is initially placed, cardiac surgeons or interventionalists can evaluate the valve function to determine whether the valve needs to be repositioned, retrieved or kept in the same position. Moreover, it allows for a controlled positioning, by slowly opening the valve stent, for a likely first-attempt correct placement.



Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts